Pharma News

Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met. The study was presented at Psoriasis 2016, the 5th Congress of the Psoriasis International Network (PIN), Paris, France.

The European Commission has granted marketing authorization for ZINBRYTA™ (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen and Abbvie announced. ZINBRYTA is a once-monthly, self-administered, subcutaneous injection.

ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, announced that its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for OBE2109 has been cleared and the company is authorized to begin enrolling patients in the Phase 2b clinical study (EDELWEISS) with OBE2109 for the treatment of endometriosis.

Sanofi, a global healthcare leader, and its vaccines global business unit Sanofi Pasteur announced a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research (WRAIR) on the co-development of a Zika vaccine candidate.

TSO3 Inc, announced that the U.S. Food and Drug Administration has cleared TSO3’s expanded indications for use (IFU’s) of its STERIZONE® VP4 Sterilizer.“Our extended IFU claims have been cleared by the FDA demonstrating the truly superior capabilities of our STERIZONE® Sterilization System,” said TSO3 President and CEO, R.M. (Ric) Rumble.

Five Prime Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to FPA144 for the treatment of gastric cancer, including cancer of the gastroesophageal junction in patients whose tumors overexpress FGFR2b. FPA144 is an anti-FGF receptor 2b (FGFR2b) humanized monoclonal antibody in clinical development as a targeted immune therapy.

Insys Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Insys’ dronabinol oral solution, SyndrosTM, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC").  Syndros is approved for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.  Syndros is currently awaiting scheduling by the U.S. Drug Enforcement Administration.

Onxeo S.A., an innovative company specialized in the development of orphan oncology therapies, announced it received a Notice of Allowance from the US Patent and Trademark Office (USPTO) relating to a key patent for its signal interfering DNA product candidate, AsiDNA.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to acquiring, developing and commercializing adjunctive cancer care and critical care drug products, announced it was discontinuing Suprenza, its FDA-approved phentermine-based product for weight loss.